User login
Key clinical point: Frontline treatment with dasatinib was effective, with an acceptable safety profile in older patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP).
Major finding: Overall, 93.3%, 77.7%, and 53.3% of patients achieved a complete cytogenic response, major molecular response, and deep molecular response, respectively. At 36 months, cumulative event-free survival and overall survival were 64.7% and 82.3%, respectively. Grade 3 and 4 adverse events were observed in 13.3% and 26.6% of patients, respectively. Treatment discontinuation and dasatinib dose reduction was reported in 20.0% and 53.3% of patients, respectively.
Study details: This retrospective study included 45 older (age ≥75 years) patients with newly diagnosed CML-CP treated with frontline dasatinib followed up for a median duration of 42.6 months.
Disclosures: No source of funding was identified. Some investigators, including the lead author, reported receiving honoraria from various pharmaceutical companies.
Source: Stagno F et al. Acta Oncol. 2021;69(11):1527-1533. doi: 10.1080/0284186X.2021.1971292.
Key clinical point: Frontline treatment with dasatinib was effective, with an acceptable safety profile in older patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP).
Major finding: Overall, 93.3%, 77.7%, and 53.3% of patients achieved a complete cytogenic response, major molecular response, and deep molecular response, respectively. At 36 months, cumulative event-free survival and overall survival were 64.7% and 82.3%, respectively. Grade 3 and 4 adverse events were observed in 13.3% and 26.6% of patients, respectively. Treatment discontinuation and dasatinib dose reduction was reported in 20.0% and 53.3% of patients, respectively.
Study details: This retrospective study included 45 older (age ≥75 years) patients with newly diagnosed CML-CP treated with frontline dasatinib followed up for a median duration of 42.6 months.
Disclosures: No source of funding was identified. Some investigators, including the lead author, reported receiving honoraria from various pharmaceutical companies.
Source: Stagno F et al. Acta Oncol. 2021;69(11):1527-1533. doi: 10.1080/0284186X.2021.1971292.
Key clinical point: Frontline treatment with dasatinib was effective, with an acceptable safety profile in older patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP).
Major finding: Overall, 93.3%, 77.7%, and 53.3% of patients achieved a complete cytogenic response, major molecular response, and deep molecular response, respectively. At 36 months, cumulative event-free survival and overall survival were 64.7% and 82.3%, respectively. Grade 3 and 4 adverse events were observed in 13.3% and 26.6% of patients, respectively. Treatment discontinuation and dasatinib dose reduction was reported in 20.0% and 53.3% of patients, respectively.
Study details: This retrospective study included 45 older (age ≥75 years) patients with newly diagnosed CML-CP treated with frontline dasatinib followed up for a median duration of 42.6 months.
Disclosures: No source of funding was identified. Some investigators, including the lead author, reported receiving honoraria from various pharmaceutical companies.
Source: Stagno F et al. Acta Oncol. 2021;69(11):1527-1533. doi: 10.1080/0284186X.2021.1971292.